Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AGIO
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.8 billion
  • Outstanding Shares: 48,204,000
Average Prices:
  • 50 Day Moving Avg: $53.89
  • 200 Day Moving Avg: $50.36
  • 52 Week Range: $35.84 - $67.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.27
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $49.12 million
  • Price / Sales: 57.04
  • Book Value: $7.25 per share
  • Price / Book: 8.02
  • EBIDTA: ($238,380,000.00)
  • Net Margins: -491.54%
  • Return on Equity: -71.20%
  • Return on Assets: -40.14%
  • Current Ratio: 6.15%
  • Quick Ratio: 6.15%
  • Average Volume: 529,568 shs.
  • Beta: 1.93
  • Short Ratio: 13.43
Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.80) by $0.24. The business earned $10.51 million during the quarter, compared to analyst estimates of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm's revenue was down 66.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.64) EPS. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

11 brokers have issued 1-year target prices for Agios Pharmaceuticals' shares. Their predictions range from $45.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $62.88 in the next year. View Analyst Ratings for Agios Pharmaceuticals.

What are analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. Cann analysts commented, "This dinner and discussion with management, experts, and investors offered an update on AG-120 and an in-depth look at AG-221. Takeaways for AG-221 focused on outcomes and commercial use. AG-221 was found to have remarkable outcomes, especially in light of the difficult-to-treat population in the study. The enthusiasm expressed by Drs." (6/11/2017)
  • 2. According to Zacks Investment Research, "Agios's shares have outperformed the Medical-Products industry so far this year. As a development-stage company, Agios depends heavily on Celgene for revenues. However, the collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. In terms of the company’s pipeline, most of the candidates are in mid and early stages of development and thus, several years away from entering the market. Moreover, the decision to discontinue the development of AG-519 is disappointing. Stiff competition is another matter of concern for the company. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (4/28/2017)
  • 3. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

  • David P. Schenkein M.D., President, Chief Executive Officer, Director
  • Andrew Hirsch, Chief Financial Officer
  • Scott Biller Ph.D., Chief Scientific Officer
  • Christopher Bowden M.D., Chief Medical Officer
  • Steven L. Hoerter, Chief Commercial Officer
  • Lewis Clayton Cantley Ph.D., Director
  • David Scadden M.D., Director
  • Paul J. Clancy, Independent Director
  • Ian T. Clark, Independent Director
  • Kaye I. Foster-Cheek, Independent Director

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Handelsbanken Fonder AB (0.21%), Hamilton Lane Advisors LLC (0.12%), Handelsinvest Investeringsforvaltning (0.06%), Creative Planning (0.03%), Public Employees Retirement Association of Colorado (0.01%) and Parametrica Management Ltd (0.01%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd., Clear Harbor Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Hamilton Lane Advisors LLC, Handelsinvest Investeringsforvaltning, Parametrica Management Ltd, Aperio Group LLC, Public Employees Retirement Association of Colorado and Creative Planning. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $58.12.

MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $62.88 (8.18% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
6/11/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$75.00MediumView Rating Details
6/11/2017CannReiterated RatingBuy$75.00MediumView Rating Details
5/18/2017Canaccord GenuitySet Price TargetBuy$90.00MediumView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingOutperform$61.00HighView Rating Details
2/16/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
12/19/2016Leerink SwannReiterated RatingMarket Perform$56.00 -> $45.00N/AView Rating Details
12/16/2016Needham & Company LLCReiterated RatingBuy$60.00 -> $54.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$46.00N/AView Rating Details
6/13/2016J P Morgan Chase & CoUpgradeNeutral -> Overweight$50.00 -> $62.00N/AView Rating Details
5/18/2016SunTrust Banks, Inc.Boost Price TargetBuy$57.00 -> $65.00N/AView Rating Details
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($1.56)N/AView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
2017 EPS Consensus Estimate: ($7.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.86)($1.78)($1.81)
Q2 20173($1.92)($1.80)($1.88)
Q3 20172($1.98)($1.96)($1.97)
Q4 20171($1.95)($1.95)($1.95)
(Data provided by Zacks Investment Research)


Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 84.22%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.00View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.00View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.00View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.00View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.00View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.00View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.60View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.00View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.30View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.64View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.00View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.96View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.00View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.68View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.00View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.00View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Agios Pharmaceuticals (NASDAQ:AGIO)
Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline logoCommit To Purchase Agios Pharmaceuticals At $45, Earn 10.9% Annualized Using Options - Nasdaq - July 26 at 3:38 PM logoWhat's in Store for Agios Pharma (AGIO) in Q2 Earnings? - July 26 at 3:38 PM logoAgios Pharmaceuticals, Inc. (AGIO) Scheduled to Post Quarterly Earnings on Wednesday - July 26 at 7:12 AM logoAgios Pharmaceuticals, Inc. (AGIO) Given Average Rating of "Buy" by Brokerages - July 24 at 12:11 PM logoAgios Pharmaceuticals, Inc. (AGIO) Director Sells $196,490.00 in Stock - July 21 at 7:31 PM logoInsider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells 9,000 Shares of Stock - July 21 at 7:30 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Upgraded to "Buy" by BidaskClub - July 16 at 4:00 PM logoZacks: Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $11.52 Million - July 16 at 8:16 AM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expected to Announce Earnings of -$1.52 Per Share - July 14 at 4:48 PM logoNewman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO - Business Wire (press release) - July 12 at 4:03 PM logoNewman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO - July 12 at 4:03 PM logoInsider Selling: Agios Pharmaceuticals, Inc. (AGIO) Insider Sells 2,146 Shares of Stock - July 11 at 8:20 PM logoDavid P. Schenkein Sells 3,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock - July 6 at 8:04 PM logoAgios/Celgene's Leukemia Candidate Positive in Phase I/II - June 27 at 8:30 PM logoAgios/Celgene's Leukemia Candidate Positive in Phase I/II - Nasdaq - June 27 at 3:29 PM logoAgios/Celgene's Leukemia Candidate Positive in Phase I/II - June 27 at 3:29 PM logoAgios Pharmaceuticals, Inc. (AGIO) Receives Average Recommendation of "Buy" from Analysts - June 27 at 12:34 PM logoMid-Morning Market Update: Markets Open Higher; Durable-Goods Orders Fall 1.1% - Benzinga - June 26 at 8:55 PM logo12 Biggest Mid-Day Losers For Monday | Benzinga - Benzinga - June 26 at 8:55 PM logoMid-Morning Market Update: Markets Open Higher; Durable-Goods Orders Fall 1.1% - June 26 at 3:53 PM logoAgio Pharma Sinks on Midstage Trial - June 26 at 3:53 PM logoBiotech Rally Stumbles As These Small Caps Pull Back - June 26 at 3:53 PM logoAgios Pharmaceuticals, Inc. (AGIO) Cut to Neutral at Janney Montgomery Scott - June 26 at 12:16 PM logoAgios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating ... - June 25 at 8:35 PM logoAgios Pharmaceuticals, Inc. (AGIO) Upgraded to Hold by ValuEngine - June 25 at 12:10 AM logoAgios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as ... - Benzinga - June 24 at 8:26 PM logoAgios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017 - June 24 at 8:26 PM logoAgios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as the First ... - GlobeNewswire (press release) - June 24 at 3:25 PM logoAgios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency - June 24 at 3:24 PM logoNew Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML - June 24 at 3:24 PM logoScott Biller Sells 4,292 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock - June 23 at 7:32 PM logoCelgene: I Don't Necessarily Understand The Science, But I Love The Numbers - Seeking Alpha - June 22 at 3:23 PM logoAgios Pharmaceuticals, Inc. (AGIO) Expected to Post Quarterly Sales of $11.52 Million - June 22 at 10:35 AM logoMyelodysplastic Syndrome Pipeline Therapeutic Drugs and ... - MarketWatch - June 21 at 2:09 AM logo-$1.52 EPS Expected for Agios Pharmaceuticals, Inc. (AGIO) This Quarter - June 20 at 2:24 PM logoAgios Pharmaceuticals, Inc. (AGIO) Director Sells $101,740.00 in Stock - June 15 at 7:42 PM logoETFs with exposure to Agios Pharmaceuticals, Inc. : June 15, 2017 - June 15 at 4:59 PM logoAgios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : June 14, 2017 - June 14 at 3:25 PM logoAgios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : June 13, 2017 - June 13 at 11:38 AM logoAgios Pharmaceuticals, Inc. (AGIO) PT Set at $75.00 by Oppenheimer Holdings, Inc. - June 11 at 11:32 PM logoAgios Pharmaceuticals' (AGIO) "Buy" Rating Reaffirmed at Cann - June 11 at 9:34 PM logoInsider Selling: Agios Pharmaceuticals Inc (AGIO) CEO Sells 3,000 Shares of Stock - June 8 at 7:52 PM logoAgios (AGIO) Up 2.6% Since Earnings Report: Can It Continue? - Nasdaq - June 8 at 8:01 AM logoAgios (AGIO) Up 2.6% Since Earnings Report: Can It Continue? - June 8 at 8:00 AM logoCelgene and Agios Announce Data on Idhifa for Leukemia - June 7 at 3:30 PM logoUpdated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 ... - June 7 at 5:13 AM logoCelgene (CELG) & Agios Pharmaceuticals (AGIO) Presents Updated Data from Phase 1 Trial of Oral IDHIFA (Enasidenib) - June 7 at 5:13 AM logoBRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30 - June 7 at 5:13 AM logoBRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30 - Reuters - June 6 at 3:37 PM logoCelgene (CELG) & Agios Pharmaceuticals (AGIO) Presents Updated ... - - June 6 at 3:37 PM



Agios Pharmaceuticals (AGIO) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff